




A. Subject

CAR-T Medications – Breyanzi (lisocabtagene maraleucel)

B. Background Chimeric antigen receptor T-cell therapy (CAR-











H. References

- 1. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839-852.
- 2. Breyanzi (lisocabtagene maraleuce) [package insert]. Bothell, WA; Juno Therapeutics, Inc.; Revised 02/2021.
- 3. Bristol-Myers Squibb Company. Breyanzi (lisocabtagene maraleuce) Risk Evaluation and Mitigation Strategy (REMS) (2021, March). Retrieved January 28, 2022 from www.breyanzirems.com.